Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on May 27, 2011. The report details a material definitive agreement entered into on the same date with the US Army Medical Research and Material Command (USAMRMC).
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. The primary financial event reported is a grant award of approximately $5.6 million.
- Grant Amount: Approximately $5.6 million.
- Grant Purpose: Support for the development of product candidate ARX-04 (a sublingual product for acute pain).
- Grant Period: June 1, 2011, to August 31, 2012.
Material Changes
The material change reported is the entry into the award contract with the USAMRMC. This agreement provides funding to reimburse the Company for development, manufacturing, and clinical costs associated with a Phase 2 dose-finding trial for ARX-04. The trial is scheduled to begin in the second half of 2011.
Outlook and Management Commentary
Management indicated that the grant will support the completion of a Phase 2 study and preparation for Phase 3 development. The USAMRMC retains the option to extend the grant term and provide additional funding. The Company publicly announced this contract via a press release on May 31, 2011.
Investor Verification Checklist
- Verify the specific terms and reimbursement conditions of the $5.6 million USAMRMC grant.
- Confirm the timeline for the commencement of the Phase 2 dose-finding trial for ARX-04.
- Review the attached press release (Exhibit 99.1) for additional details on the product candidate.
- Monitor future filings for updates on the grant's utilization and the option for extension.